Elena Viterbo-Noble, MD
Family Medicine · Williamsburg, VANPI 1992802722
Payments from drug & device makers
Across 298 payments — averaging $17.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$692
- Amgen$586
- Novo Nordisk$548
- Axsome Therapeutics, Inc.$507
- AstraZeneca$386
- Pfizer$373
- plus $2K from 30 others
What the payments were for
- Food & beverage$5,12499%
- Education$281%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 48 | $692 |
| Amgen | 36 | $586 |
| Novo Nordisk | 33 | $548 |
| Axsome Therapeutics, Inc. | 27 | $507 |
| AstraZeneca | 25 | $386 |
| Pfizer | 20 | $373 |
| GSK | 21 | $354 |
| Lilly USA, LLC | 21 | $335 |
| Boehringer Ingelheim | 12 | $216 |
| Otsuka America Pharmaceutical, Inc. | 9 | $175 |
| Amarin Pharma, Inc. | 8 | $171 |
| Insightec,inc | 2 | $98 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $80 |
| Corcept Therapeutics | 2 | $53 |
| Merck | 3 | $51 |
| Johnson & Johnson | 3 | $46 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $40 |
| Amneal Pharmaceuticals LLC | 2 | $37 |
| Sanofi Pasteur Inc. | 2 | $34 |
| Esperion Therapeutics, Inc. | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
| Inspire Medical Systems, Inc. | 1 | $27 |
| Phadia US Inc. | 1 | $26 |
| Astellas Pharma US Inc | 1 | $24 |
| Exact Sciences | 1 | $24 |
| Biohaven Pharmaceuticals, Inc. | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Dexcom, Inc. | 1 | $22 |
| Supernus Pharmaceuticals, Inc. | 1 | $21 |
| Philips North America LLC | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Genentech USA, Inc. | 1 | $19 |
| Grifols USA, LLC | 1 | $17 |
| Watermark Medical, Inc. | 1 | $15 |
| Novartis | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
How this compares
$5,152 in reported general payments places this provider in the 85th percentile of 2,553 family medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 37 | $72,032 |
| EliquisApixaban | 42 | $56,194 |
| JardianceEmpagliflozin | 29 | $45,399 |
| OzempicSemaglutide | 32 | $45,162 |
| FarxigaDapagliflozin Propanediol | 22 | $26,583 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 12 | $19,007 |
| Repatha SureclickEvolocumab | 12 | $11,059 |
| VascepaIcosapent Ethyl | 16 | $7,464 |
| SynthroidLevothyroxine Sodium | 87 | $5,509 |
| Rosuvastatin Calcium | 252 | $3,061 |
| Atorvastatin Calcium | 380 | $2,762 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 14 | $2,725 |
| Valsartan | 79 | $2,262 |
| Metoprolol Succinate | 122 | $2,053 |
| Losartan Potassium | 169 | $1,880 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $335 | $72,03237 claims |
| PfizerEliquis | $373 | $56,19442 claims |
| Boehringer IngelheimJardiance | $216 | $45,39929 claims |
| Novo NordiskOzempic | $548 | $45,16232 claims |
| AstraZenecaFarxiga | $386 | $26,58322 claims |
| MerckJanumet Xr | $51 | $19,00712 claims |
| AbbVieSynthroid | $692 | $5,50987 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $37 | $2,425213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,553 family medicine providers in Virginia.
Other family medicine in Williamsburg
- Monique SesslerWilliamsburg$22K
- Aaron HartmanMidlothian$17.4M
- John ScottGlen Allen$16.7M
- Banu MyneniPortsmouth$12.8M
- Patricia HouserWinchester$3.5M
- Stephan JannachDanville$3M
- Linda SchneiderHampton$2.1M
- Jennifer BrownMidlothian$1.3M
- Brian McCormickHampton$793K
- Jerome DanielNorth Chesterfield$779K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.